Trial Profile
A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy (AVF4572)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 May 2021 Status changed from active, no longer recruiting to completed.
- 23 Jul 2020 Planned End Date changed from 1 Mar 2020 to 1 May 2022.
- 23 Jul 2020 Planned primary completion date changed from 1 Mar 2020 to 1 May 2021.